Clinical trial
A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage…
NCT00480831 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00480831 |
|---|---|
| Title | A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g) |
| Official title | A Randomized, Double-Blind, Phase II Trial of Paclitaxel + Carboplatin + Bevacizumab With or Without PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | bevacizumab, carboplatin, paclitaxel, placebo, PRO95780 |
| Enrollment | 128 |
| Start date | Jun 1, 2007 |
| Primary completion | Aug 1, 2010 |
| Completion | Aug 1, 2010 |
| First posted | May 31, 2007 |
| Last update posted | May 18, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: